Clinical trials: Non-myeloid Malignancies
Hematological Malignancies
Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT
The primary goal of the study is to determine the incidence and severity of acute Graft versus Host Disease (GVHD) following human leukocyte antigen (HLA) matched related donor Hematopoetic Stem Cell(HSC) transplant in patients…
- Trial name
- NCT01246206
- Testing
- Tacrolimus and Thymoglobulin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Non-Hodgkin's Lymphoma or Hodgkin's Disease, Acute Leukaemia
Palifermin After Haploidentical PBSCT
This is a double blind, placebo controlled clinical trial, where patients with an advanced form of blood cancer are treated with haploidentical allogeneic peripheral blood progenitor cell (PBPC) transplant after which they are…
- Conditions
- Non-Hodgkin's Lymphoma or Hodgkin's Disease, Acute Leukaemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia
- Trial name
- KGF Haplo Allo (NCT00570999)
- Testing
- Palifermin
- Where
- Germany
- Sponsor
- European Society for Blood and Marrow Transplantation
Hodgkin's Lymphoma, Leukemia
Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation
The goal of this project is to refine and evaluate the feasibility of a brief, behavioral intervention to improve the recovery following hematopoietic stem cell transplantation (HSCT).
- Conditions
- Hodgkin's Lymphoma, Leukemia, Lymphoid Leukemia, Multiple Myeloma
- Trial name
- NCT02719821
- Testing
- Behavioral techniques
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Wisconsin, Madison
Pyruvate Kinase Deficiency, Pyruvate Kinase Deficiency Anemia
Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms
This cross-sectional prevalence assessment study involves a single blood draw in specific patient populations to assess for enzymatic and genomic evidence for acquired pyruvate kinase deficiency.
- Conditions
- Pyruvate Kinase Deficiency, Pyruvate Kinase Deficiency Anemia, Hereditary Hemolytic Anemia, Myelodysplastic Syndromes
- Trial name
- NCT04902833
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Massachusetts General Hospital
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Bone marrow and peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00004232
- Testing
- filgrastim, cyclosporine, methylprednisolone
- Where
- United States
- Sponsor
- Northwestern University
Leukemia, Lymphocytic, Acute, Leukemia, Lymphocytic, Chronic
Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit
This study is a means of providing transplantation to those patients who would be a stem cell transplant candidate who do not have an appropriate donor.
- Conditions
- Leukemia, Lymphocytic, Acute, Leukemia, Lymphocytic, Chronic, Leukemia, Myelocytic, Acute, Leukemia, Myeloid, Chronic
- Trial name
- Haplo/Cord (NCT01050946)
- Testing
- Haploidentical/cord transplant
- Volunteers
- 1 people
- Sponsor
- Medical College of Wisconsin
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)
The purpose of the study is to compare overall response rate (ORR) between treatment groups in participants with higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) who are not eligible for…
- Trial name
- NCT04264806
- Testing
- Azacitidine, Cusatuzumab
- Where
- 73 sites in Australia, Brazil and 9 more
- Sponsor
- Janssen Research & Development, LLC
Non Small Cell Lung Cancer Stage IIIB
Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy
Metastatic non small cell lung cancer can be treated with cytotoxic chemotherapy or using recently approved immunotherapy with antibody, Nivolumab.
- Trial name
- NCT03302247
- Testing
- Nivolumab, Nivolumab+Gemcitabine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Fox Chase Cancer Center
Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
This randomized pilot clinical trial studies how well giving prolonged infusion compared to standard infusion of cefepime hydrochloride works in treating patients with febrile neutropenia.
- Conditions
- Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia, Adult Burkitt Lymphoma, Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT01484015
- Testing
- cefepime hydrochloride
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Wake Forest University Health Sciences
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy
This phase II trial studies how well sirolimus and azacitidine works in treating patients with high-risk myelodysplastic syndrome or recurrent acute myeloid leukemia.
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Trial name
- NCT01869114
- Testing
- Sirolimus, Azacitidine
- Where
- 5 sites in United States
- Volunteers
- 57 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
This phase II trial studies reduced-intensity conditioning before donor stem cell transplant in treating patients with high-risk hematologic malignancies.
- Conditions
- Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM, Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214
- Trial name
- NCT01760655
- Testing
- Fludarabine phosphate, Busulfan, Total-Body Irradiation
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Acute Myeloid Leukaemia
Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.
This is a Phase I/II clinical study to determine the maximum tolerated dose (MTD), and schedule, safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD2811 monotherapy or with combination agent(s) in…
- Trial name
- NCT03217838
- Testing
- AZD2811, Azacitidine, Venetoclax
- Where
- 11 sites in United States, Australia
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndromes
Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy
Phase I/II trial to study the effectiveness of liposomal daunorubicin and SU5416 in treating patients who have hematologic cancer that has not responded to initial therapy.
- Conditions
- Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts
- Trial name
- NCT00005942
- Testing
- liposomal daunorubicin citrate, semaxanib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Adult
Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features
Individualized induction therapy will be applied to the non-elderly acute myeloid leukemia (AML) patients with adverse genetic risk features guided by rapid screening with fluorescence in situ hybridization (FISH) and…
- Trial name
- NCT04752527
- Testing
- venetoclax combined with decitabine
- Where
- China
- Volunteers
- 42 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Chronic Myeloproliferative Disorders, Leukemia
12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004058
- Testing
- tetradecanoylphorbol acetate
- Where
- United States
- Sponsor
- University of Medicine and Dentistry of New Jersey
Lung Neoplasms, Myeloid-Derived Suppressor Cells
Role of MDSCs and Cancer Stem Cells and Their Cross Talks in NSCLC
Immunotherapy have revolutionized the field of oncology, but response rates are low and all patients relapse, due to cellular and soluble immunosuppressive mechanisms.
- Conditions
- Lung Neoplasms, Myeloid-Derived Suppressor Cells, Immunosuppression
- Trial name
- MyéloLungSC (NCT06024226)
- Testing
- Tumor samples
- Where
- France
- Volunteers
- 10 people
- Sponsor
- University Hospital, Bordeaux
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Studying Fentanyl in Patients With Cancer
RATIONALE: Studying blood samples from cancer patients undergoing pain treatment in the laboratory may help doctors learn more about how pain drugs work in the body.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00899951
- Testing
- fentanyl citrate, pharmacological study
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML)
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
Patients less than or equal to 21 years old with high-risk hematologic malignancies who would likely benefit from allogeneic hematopoietic cell transplantation (HCT).
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), NK-Cell Leukemia
- Trial name
- NCT03849651
- Testing
- Cyclophosphamide, Fludarabine, Thiotepa
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- St. Jude Children's Research Hospital
Leukemia, Myelodysplasia
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
This is an open label, non-randomized, multicenter, pilot, dose expansion study of low dose post-transplant cyclophosphamide (25 mg/kg on Days +3 and +4)/tacrolimus/ruxolitinib in the setting of myeloablative conditioning (MAC)…
- Conditions
- Leukemia, Myelodysplasia, Chronic Myelomonocytic Leukemia
- Trial name
- NCT07249346
- Testing
- Ruxolitinib, Myeloablative conditioning regimen, Hematopoietic Stem Cell Transplantation
- Where
- 3 sites in United States
- Volunteers
- 124 people
- Sponsor
- Hannah Choe, MD
Acute Myelogenous Leukemia, Myelogenous Leukemia
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
This is a Phase 1b, open-label, non-randomized, multicenter study to evaluate the safety and pharmacokinetics of orally administered venetoclax (ABT-199) combined with decitabine or azacitidine and the preliminary efficacy of…
- Conditions
- Acute Myelogenous Leukemia, Myelogenous Leukemia, Treatment Naive AML
- Trial name
- NCT02203773
- Testing
- Posaconazole, ABT-199, Decitabine
- Where
- 23 sites in United States, Australia and 2 more
- Volunteers
- 212 people
- Sponsor
- AbbVie